Home  >  News
you can get e-magazine links on WhatsApp.Click here
Pharmacy & Trade + Font Resize -

MTPA announces PANTHERx selected as exclusive provider of US specialty pharmacy services for Exserva oral film

Jersey City, New Jersey
Monday, June 28, 2021, 17:00 Hrs  [IST]

Mitsubishi Tanabe Pharma America, Inc. (MTPA) announced PANTHERx Rare Pharmacy has been selected as the exclusive provider of specialty pharmacy services for Exservan (riluzole), an oral film formulation of riluzole for the treatment of amyotrophic lateral sclerosis (ALS).

"As we explored options for specialty pharmacy partners for the distribution of Exservan, it was important to find an organization with specific knowledge and experience that could best support the ALS community," said Kevin O'Brien, vice president of market access, MTPA. "PANTHERx is able to deliver on both fronts, in addition to also having an unwavering dedication to patients. This is closely aligned with our commitment to helping patients."

Once a patient is prescribed Exservan, they may be enrolled in access information services. Upon enrollment, PANTHERx will provide patients with a review and summary of insurance benefit options, including information about eligibility for the Out-of-Pocket Assistance Programme for Exservan.

MTPA plans to make Exservan available to patients by the end of June 2021.

"PANTHERx prides itself on being focused on people living with the implications of rare disease," said Rob Snyder, President of PANTHERx. "We hope our extensive experience will positively impact the members of the ALS community that we aim to serve through our dispensing of Exservan. We look forward to working with MTPA to help address the needs of people impacted by this devastating disease."

Exservan, an oral film formulation of riluzole, was approved by the US Food and Drug Administration (FDA) in November 2019. Exservan was developed by Aquestive Therapeutics, Inc. using its PharmFilm innovative drug delivery technology. The oral film is placed on top of the patient's tongue and dissolves. Under the terms of a licensing and supply deal agreement, MTPA is commercializing Exservan in the US and Aquestive is serving as the exclusive sole manufacturer and supplier for the product.

Exservan (riluzole) is indicated for the treatment of amyotrophic lateral sclerosis (ALS).

Based in Jersey City, New Jersey, Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100 per cent owned US holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. It was established by MTPC to commercialize approved pharmaceutical products in North America.


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |